Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy-Reference-Cited by-同舟云学术

Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy

Published:2023-03 Issue: Volume:181 Page:53-61
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hondelink Liesbeth M.^ORCID,Ernst Sophie M.^ORCID,Atmodimedjo Peggy,Cohen Danielle,Wolf Janina L.^ORCID,Dingemans Anne-Marie C.,Dubbink Hendrikus J.^ORCID,von der Thüsen Jan H.^ORCID

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?;Le Chevalier;Ann Oncol,2010

2. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies;Kratz;Lancet,2012

3. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

4. Osimertinib in resected EGFR-mutated non-small-cell lung cancer;Wu;N Engl J Med,2020

5. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study;Cancers;2024-07-19

2. Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study;Journal of Thoracic Oncology;2024-06

3. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.;BMC Cancer;2024-03-25

4. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection;Clinical Lung Cancer;2024-01

5. Distinguishing EGFR mutant subtypes in stage IA non-small cell lung cancer using the presence status of ground glass opacity and final histologic classification: a systematic review and meta-analysis;Frontiers in Medicine;2023-12-06